Monday, February 11th, 2:00pm - 2:55pm
The primordial soup of private biotech was supposed to give rise to a stronger, broader public market and provide mature companies with new sources of competitive advantage in the form of in-licensed drug candidates. However, the VC world is shrinking and in 2012 we hit the lowest number of first time financings for biotechs in 15 years. The number of firms investing in biotech has also decreased substantially and new patents at tech transfer offices are collecting dust. While pharma venture and philanthropic venture firms are stepping into the void, other private funding sources have moved to public markets with PIPEs and VIPEs. Will the drop in private funding be a future headache for the public investor that has long depended on new technologies percolating up to public exchanges? As players and strategies are shifting at the private/public intersection, and new financing models are being tested, what should the public investor be aware of? Are there new compelling investing opportunities in 2013 on the private side?
Jeffrey Baumel, Partner, SNR Denton
Arlene M. Morris, Chief Executive Officer, Syndax Pharmaceuticals
Stelios Papadopoulos, PhD, Chairman, Exelixis, Inc.
Dennis Purcell, Senior Managing Partner, Aisling Capital
David Sable, Portfolio Manager, Special Situations Fund